Purpose: In the years 1993-1996 a number of presumably false-positive breast cancer diagnoses were made by a pathologist in Essen. A follow-up, undertaken 15 years later, investigated how many women had tumour recurrence and/ or metastasis or had died from breast cancer. Material and Methods: A total of 151 (68%) out of 222 women could be traced. One hundred and
forty-seven (66.2%) of the 222 women were alive. The observed survival rate, number of recurrences and/or metastases, and number of deaths from breast cancer were compared with data from the Munich Tumour Registry. The number of breast cancer cases among daughters of the affected women was ascertained. Results: The total observed survival rate at follow-up after 15 years was 93 %, a much higher figure than the survival rate of 45% given by the Munich Tumour Registry. Recurrence and/or metastasis or death from breast cancer occurred in 9/ 222 cases (4.1 %). The incidence for these events calculated according to data from the Munich Tumour Registry is 13 %. Two daughters (2.2%) out of a total of 90 were diagnosed with breast cancer whereas, according to the German Cancer Research Centre, the expected rate would have been between 5 and 10 %. Conclusions: The results of our follow-up after 15 years show that more women survived than expected and that the number of recurrences and/ or metastases and deaths due to breast cancer was lower than expected. Fewer daughters of affected women were diagnosed with breast cancer than expected. These results support our suspicion that not all women diagnosed with breast cancer by a pathologist in Essen actually had breast cancer. In the years 1993-1996 a number of presumably false-positive breast cancer diagnoses were made in Essen by a pathologist (Prof. Dr. Kemnitz). The suspicion that these diagnoses were false-positive arose because the data showed unusually high numbers of women with early stage breast cancer in Essen. Based on this information, a gynaecologist requested that the pathologist hand over tissue samples of his patients for re-examination by a second specialist. Examination confirmed the suspicion of wrongful breast cancer diagnoses. A charge was brought against the pathologist for bodily injury caused by negligence. In 1997 the pathologist set fire to his laboratory and lost his own life in the blaze. Numerous tissue samples of patients were incinerated and so were not available as evidence. The number of women affected was estimated to be around 300. It has still not been possible to find out exactly how many women were affected [1] . The women can therefore not discover whether they actually had breast cancer or not. A statement issued in 2000 by the German Society for Senology confirmed the suspicion that not all of the women had breast cancer and that some of them had been victims of a false diagnosis [2] . The aim of this study was to investigate, through personal questioning of the affected women 15 years after the breast cancer study, how many of these women had tumour recurrence or metastasis or had died of breast cancer. A comparison was made with the previous 10-year follow-up [1] . In addition, this study also investigated how many of the women had given birth to a daughter and how many of these daughters had been diagnosed with breast cancer.
Patients and Methods

!
10-year follow-up
A total of 222 women whose data was on record were sent a written request to present themselves for their 10-year follow-up. Documentation was available for 171 women. At the time of the 10-year follow-up 7 of the 171 women had died, 2 of whom had died from breast cancer. At the time of the 10-year follow-up, 164 women were alive. Ten of the 164 women did not wish to participate but had not experienced recurrence of breast cancer or metastasis. A total of 154 women participated in the 10-year followup investigation [1] . A total of 76 (49.4%) out of 154 women had undergone mastectomy; 78 (50.6 %) of 154 cases had had breast-conserving therapy. 
15-year follow-up
The 15-year follow-up in 2010 was done by telephone interview of the affected women. Data recorded included whether tumour recurrence and/or metastasis had occurred. If the woman had died the cause of death was determined through the questioning of family members. The number of daughters and their ages were recorded. The number of daughters who had been diagnosed with breast cancer was noted. In addition, the women were asked whether they had received any financial compensation.
Definitions
With regard to ipsilateral and contralateral local tumour manifestations which developed during the follow-up period it was assumed, in view of the diagnosis of breast cancer that had been made and for epidemiological analysis, that all of these cases were tumour recurrences. Similarly, metastases which developed during follow-up were attributed to the primary diagnosis of breast cancer. Tumour progression was defined as the development of tumour recurrence or metastasis or death due to breast cancer.
Statistical analysis
The first analysis calculated the total probability of survival for the women investigated in this study at 15-and 10-year followup. This data was then compared with figures from the Munich Tumour Registry [3, 4] . This analysis was expanded further by the additional calculation of survival probabilities for specific tumour stages. For this, the distribution of tumour stage-specific survival probabilities of the Munich Tumour Registry [4] was used to estimate the tumour stage-specific survival probability 
15-Jahres-Verlaufskontrolle
Statistische Auswertung
In der ersten Analyse erfolgte die Berechnung der in dieser Studie beobachteten Gesamtüberlebenswahrscheinlichkeit der betroffenen Frauen für 15 und 10 Jahre Follow-up. Diese wurde mit den Angaben des Tumorregisters München verglichen [3, 4] Table 2 Characteristics of patients with tumour recurrence and/or metastasis, n = 7 (modified in accordance with [1] ).
Pat.
No. Interval to metastasis (years)
Year
n. k.= not known, -= no operation, --= no recurrence, no metastasis.
Ipsilateral is defined as the affected breast; contralateral is defined as the other breast.
* Died in the interval between the 10-year follow-up and the 15-year follow-up.
for our sample. This was then compared with the actually observed survival of the affected women in Essen. The distribution of tumour stages according to the Munich Tumour Registry was 50.1 % for the pT1 stage. For our collective we assumed that the increased number of tumour diagnoses were the result of an increased number of diagnoses of early stage tumours (pT1). Therefore 2 further simulations were done using higher rates for pT1 tumour diagnosis of 55 and 70 %, respectively. In a second analysis, disease progression of the affected women was compared with progression calculated using data from the Munich Tumour Registry. According to the Munich Tumour Registry, over a period of 29 years approximately 25 % of women diagnosed with breast cancer will show progression (out of a total of 34 478 women, 8621 had disease progression over a period of 29 years). Calculated for a 15-year period, this would result in a disease progression rate of 13%, and we used this figure as the basis for our analysis. In addition, we did a sensitivity analysis where we assumed that all of the women we were unable to reach or who did not participate had suffered disease progression or had died.
In a third analysis, the incidence of breast cancer among the daughters of the affected women was calculated. The figures for the incidence of breast cancer in the daughters was compared with figures from the literature [5, 6] . In a second step, the incidence of breast cancer reported in the Cancer Registry of North-Rhine Westphalia (1994 to 2008) was used to retrospectively estimate the expected cumulated incidence of breast cancer occurring in daughters for the years 1996 to 2010 and for the different age groups. To allow for the expected increased incidence in cases with a positive familial diagnosis, the expected calculated cumulated incidence was increased by 10%. Finally, these expected figures were compared with the actual numbers reported for the collective of affected women. Data analysis was carried out using Microsoft ® Excel 2007 (Microsoft Corporation, WA, USA) and SAS (Version 9.2, SAS Institute, Cary, NC, USA). Four of 151 women had died by this time. One of the 4 died due to breast cancer metastasis. This woman had already had metastasis at the 10-year follow-up. According to reports given by family members, 2/4 women died from cardiac insufficiency and one woman died due to a brain tumour. One hundred and forty-seven women were still alive and participated in the 15-year follow-up. Six of the 7 women with disease progression at the 10-year follow-up were still alive at the 15-year follow-up (l " Table 2) . l " Table 3 shows the numbers of patients who participated in the 10-year and 15-year follow-up.
Results
Mortality at 15-year follow-up l " Table 4 shows the actual total survival at the 10-year and 15year follow-up. If we take the original figure of 222 women on record and the figure of 154 women who were alive at the 10-year follow-up, subtracting the 51 women about whom no information was available, the recorded total survival rate after 10 years was 95.9 %. With regard to the 15-year follow-up and again taking the original number of 222 women into consideration, the total survival rate after 15 years after subtraction of the 64 women about whom no information was available was 93.0 % (l " Table 4 ).
If we make a conservative assumption that all the women about whom we have no information and who therefore were not followed up after 10 and 15 years all died, we could expect a total survival rate of 73.9 % after 10 years and of 66.2 % after 15 years (Simulation 1 and 3 in l " Table 4 ). By comparison, the 10-year survival rate according to the field study of the Munich Tumour Registry was 59 % and the survival rate after 15 years was 45 % (l " Table 5 ). Compared to the Munich Tumour Registry the total survival rate for the women in our study after 10 and 15 yearseven when we assumed the worst prognosiswas therefore 14.9 percentage points (73.9 vs. 59 %) and 21.2 percentage points (66.2 vs. 54 %) higher (l " Table 5 ).
The results of our analysis of survival probability (total survival) after 15 years according to the distribution of tumour stages at first diagnosis using the Munich field study are shown in l " Fig. 1 . The observed total survival of 147 affected women thus clearly exceeded the expected figure of 99 women.
Mortalität in der 15-Jahres-Verlaufskontrolle l " Tab. 4 zeigt das beobachtete Gesamtüberleben in der 10-Jahres-Verlaufskontrolle und 15-Jahres-Verlaufskontrolle. Unter Berücksichtigung der ursprünglich 222 aktenkundigen Frauen und der in der 10-Jahres-Verlaufskontrolle 154 lebenden Frauen ergibt sich nach Subtraktion der 51 Frauen, von denen wir keine Informationen haben, ein beobachtetes Gesamtüberleben nach 10 Jahren von 95,9 %. Bezüglich der 15-Jahres-Verlaufskontrolle ergibt sich unter Berücksichtigung der ursprünglich 222 aktenkundigen Frauen und der 147 lebenden Frauen nach Subtraktion der 64 Frauen, von denen wir keine Informationen haben, ein beobachtetes Gesamtüberleben nach 15 Jahren von 93,0 % (l " Tab. 4).
Unter der konservativen Annahme, dass die Frauen, bei denen wir keine Informationen haben und folglich keine 10-Jahresund keine 15-Jahres-Verlaufskontrolle möglich war, alle verstorben sind, wäre nach 10 Jahren ein Gesamtüberleben von 73,9 % und nach 15 Jahren ein Gesamtüberleben von 66,2 % zu erwarten gewesen (Simulation 1 und 3 in l " Tab. 4 Table 4 b Simulation 1, cf. l " Table 4 c Simulation 4, cf. l " Table 4 d Simulation 3, cf. l " Table 4 As the distribution of tumour stages showed an above average number of early tumour stages (tumour stages which have a better prognosis) among the affected women, an additional analysis with a higher percentage of T1 stage tumours was carried out (l " Fig. 2 ). Using a simulation with a share of 55.0 % pT1 a total of 103 women could have been expected to survive. Using a simulation with a share of 70% pT1 the total number of women expected to survive was 112. However the observed total number of women who survived in our study was at least 147 and thus much higher.
Tumour progression
At the 10-year follow-up, 9 of the 222 (4.1 %) women on record reported disease progression. At the 15-year follow-up no new cases of recurrence or metastasis were noted. One woman with metastases at the time of the 10-year follow-up had died in the interim period, so that the total number of women with tumour progression remained the same (l " Table 2 ). By comparison, the expected number of women with disease progression using data from the long-term study of the Munich Tumour Registry would have been 29 (13 %) out of 222 women. In a sensitivity analysis it was additionally assumed that disease progression would have occurred in 13 % of the 64 women for whom we were unable to obtain information for our study. Fig. 1 Expected and observed total survival in 2010 for 222 women for whom a normal distribution of tumour stages was assumed at the time of diagnosis (1993) (1994) (1995) (1996) . Distribution of stages and expected total survival based on [4] . TU stages = tumour stages; y = years; n = number of women. (l " Table 6 ), a figure which was still less than the expected number of women with disease progression. Only a worst-case scenario which assumed that all of the 64 women for whom no information was obtainable suffered progression resulted in a distinctly higher number of women with progression than expected.
TU stage Tumour Registry
Female offspring
A total of 72 (49 %) out of 147 women gave birth to at least 1 daughter. In all, 99 daughters were born. Average age of the daughters at the time of the 15-year follow-up was 38.2 years (range: 18-51 years). No information was available for 9 daughters. Two (2.2 %) out of 90 daughters for whom we have information (ages: 36 years and 50 years) were diagnosed with breast cancer. The mothers of these daughters had no familial predisposition. In a medium scenario it was assumed that the expected incidence of breast cancer for all of the 9 daughters about whom we have no information was 10%. Using this assumption we calculated an expected incidence of 2.9 cases with breast cancer (2.9 %) among the daughters in our study (l " Table 7 ). This was compared to the average incidence in Germany for daughters of mothers with breast cancer who were also diagnosed with breast cancer, based on figures from the German Cancer Research Centre (DKFZ), of between 5 and 10 % [5, 6] . The expected calculated age-specific incidence among the general population for daughters with a positive familial diagnosis was 2.7, a figure which is only slightly higher than the number of cases observed (n = 2) (l " Table 8 ).
von Progressionen liegt. Lediglich im schlechtesten Szenario, das davon ausgeht, dass alle 64 Frauen, von denen keine Informationen vorlagen, eine Progression hatten, ist mit einer deutlich höheren Zahl von Progressionen zu rechnen als erwartet.
Weibliche Nachkommen 72/147 (49%) Frauen hatten mindestens 1 Tochter geboren. Insgesamt hatten sie 99 Töchter geboren. Das mittlere Lebensalter der Töchter war zum Zeitpunkt der 15-Jahres-Verlaufskontrolle 38,2 Jahre (18-51 Jahre). Über 9 Töchter haben wir keine Informationen. 2/90 (2,2 %) Töchter, über die wir Informationen haben (Alter: 36 Jahre und 50 Jahre) erkrankten an einem Mammakarzinom. Beide Mütter dieser Töchter hatten keine familiäre Vorbelastung. Im mittleren Szenario wurde angenommen, dass bei allen 9 Töchtern, von denen keine Informationen vorlagen, die erwartete Rate an Mammakarzinomen 10 % ist. Demnach werden in unserer Studie 2,9 Mammakarzinome (2,9%) bei den Töchtern errechnet (l " Tab. 7). Im Vergleich beträgt der deutschlandweite Durchschnitt von Töchtern mit Müttern mit Mammakarzinom, die auch an einem Mammakarzinom erkranken, nach dem Deutschen Krebsforschungszentrum (DKFZ) zwischen 5-10% [5, 6] . Die aus der alterspezifischen Inzidenz der Allgemeinbevölkerung errechnete erwartete Zahl der Fälle bei den Töchtern mit positiver Familienanamnese beträgt 2,7, was geringfügig über der beobachteten Zahl der Fälle (n = 2) liegt (l " Tab. 8). 
Finanzielle Entschädigung der Frauen
Scenarios Number Percentage
Observed figures 2/90 2.2% Best scenario: all daughters about whom we have no information do not have breast cancer 2/99 2.0% Medium scenario* 2.9/99 2.9% Worst scenario** 11/99 11.1% Average for all of Germany**: daughters of mothers with breast cancer who also have breast cancer 5-10/100 5.0-10.0 % * In the medium scenario it was assumed that 10% of the 9 daughters about whom no information could be obtained had breast cancer. Based on this assumption (9/100 × 10 = 0.9), in the medium scenario it was calculated that a total of 0.9 + 2 = 2.9 daughters would have breast cancer. In the worst scenario we assumed that all 9 daughters about whom no information could be obtained had breast cancer.
** Cancer information service of the German Cancer Research Centre (DKFZ), Krebsinformationsdienst [5] and McPherson et al. [6] .
Financial compensation for the women A total of 91/147 (62%) of the women received financial compensation from the pathologistʼs liability insurance. The last payment was made an average of 12.7 years after the event. The paying of compensation to affected women has not yet been finally concluded. Compensation payments to the women who filed an action have been made over a period of time and has depended on the number of women affected per year and the extent of the operative intervention. Fifty-six of the 147 (38%) women have received no compensation as they did not bring charges.
Discussion
!
It is still not known how many women in Essen were actually wrongly diagnosed with breast cancer in the years 1993-1996 by the pathologist. The aim of this study was therefore to find out, based on a follow-up examination after 15 years, whether the results of the 10-year follow-up would be confirmed. Our analysis showed that more affected women survived than expected and that the numbers of women with recurrence and/or metastasis and the number of deaths due to breast cancer were lower than expected. In addition, the study investigated how many of these women had given birth to daughters and how many of the daughters had been diagnosed with breast cancer.
The results of the follow-up after 15 years show that more women survived than expected and that the numbers of women with recurrence and/or metastasis and the number of deaths due to breast cancer were lower than expected. This confirms the results of our 10-year follow-up. In addition, we found that fewer daughters of affected women had been diagnosed with breast cancer than expected. These results support the suspicion that not all women diagnosed by the pathologist in Essen did indeed have breast cancer. At the 15-year follow-up we noted a total survival rate for these women of 93.0 %, which is much higher than the 45% calculated using the Munich Tumour Registry [3, 4] . Even calculations based on a worst prognosis scenario, whereby all women about whom we were unable to obtain further information had breast cancer, resulted in a total survival rate of 66.2 % which was still higher than that of the Munich Tumour Registry (45%). Similarly, we noted a higher total survival rate among the affected women, even taking higher numbers of early stage tumours in this collective into consideration compared to the figures from the field study of the Munich Tumour Registry [3, 4] . The results of the 15-year follow-up confirmed the results of the 10-year followup [1] , and thus confirmed the suspicion that a number of false diagnoses were made. In our follow-up investigations after 10 and 15 years, the recorded number of women with tumour progression was 9 (4.1 %) out of 222 cases, and thus far below the expected numbers for women with tumour progression based on the long-term study of the Munich Tumour Registry, which calculated a rate of 13 % [4] . Calculations using a medium scenario, where it was assumed that 13 % of the 64 women about whom we were unable to obtain information would have disease progression, resulted in a progression of 17.3/222 (7.7%) which was still far below the rate of 13% calculated using the Munich Tumour Registry [4] . These results again confirm the suspicion that false-positive diagnoses were made. But it is still impossible to make a definitive state- carcinoma just like anybody else in the general public. We are therefore of the opinion that the affected women should continue to be followed up and be screened for cancer. We found that the number of daughters with breast cancer, a total of 2 (2.2 %) out of 90, was far below that of the average rate for daughters of women with breast cancer in Germany (5-10 %) [5, 6] . A sensitivity analysis, in which it was assumed that 10 % of the daughters about whom we have no information, had breast cancer, still resulted in a rate which was lower than the average rate calculated for all of Germany. This confirms the suspicion that these daughters had no familial genetic predisposition. However, the uncertainty of the daughters in individual cases as to whether there may be a familial predisposition still exists. The question therefore arises whether these daughters require intensive early screening and information, both of which could be provided by breast centres. We found that the financial compensation payments were still not settled in all cases, even after 10 years. The amount paid out by the pathologistʼs liability insurance was based on the extent of the operative intervention (breast-conserving therapy vs. mastectomy) and the number of affected or operated women in the respective years between 1993 and 1996. A higher number of affected women in one year results in a lower financial compensation paid out by the pathologistʼs liability insurance to the affected individuals. In our opinion, these women still require further individually modified, early cancer screenings together with other rehabilitation measures. It would be preferable if the state provided the affected women with this care without these women being required to pay additional costs.
In the meantime, a number of certified breast centres have opened; these breast centres are obliged to comply with quality management standards and to carry out an extensive, cross-specialty documentation of patient data which may prevent such events as those which affected the women of this study from occurring in future [7] . The optimal diagnostics and therapy of patients with breast cancer requires an inter-disciplinary co-operation between radiologists, gynaecologists and/or surgeons, pathologists, oncologists, and radiation therapists. The close co-operation between different specialties in breast centres offers the best diagnostic and therapeutic opportunities and ensures that patients will receive a treatment that complies with national and international guidelines and is state-of-the-art.
Conclusions
!
The results of our 15-year follow-up show that more women survived than expected and that the numbers of women with recurrence and/or metastasis and the numbers of deaths due to breast cancer were also lower than expected. This confirms the results of our 10-year follow-up investigation. Moreover we also noted that fewer daughters of affected women were diagnosed with breast cancer than expected. These results support the suspicion that not all of the women diagnosed with breast cancer by the pathologist in Essen had breast cancer. 
